One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer.
Hudis, Clifford A. MD 1,2,
doi : 10.1200/JCO.22.02784
Volume 41(10) pgs. 1793-1954 April 1, 2023
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B; Bryant, J; Wolmark, N; Mamounas, E; Brown, A; Fisher, E R; Wickerham, D L; Begovic, M; DeCillis, A; Robidoux, A; Margolese, R G; Cruz, A B Jr; Hoehn, J L; Lees, A W; Dimitrov, N V; Bear, H D
doi : 10.1200/JCO.22.02571
To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between outcome and tumor response to preoperative chemotherapy, and if such therapy results in the performance of more lumpectomies.
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
Liedtke, Cornelia; Mazouni, Chafika; Hess, Kenneth R.; Andre[Combining Acute Accent], Fabrice; Tordai, Attila; Mejia, Jaime A.; Symmans, W. Fraser; Gonzalez-Angulo, Ana M.; Hennessy, Bryan; Green, Marjorie; Cristofanilli, Massimo; Hortobagyi, Gabriel N.; Pusztai, Lajos
doi : 10.1200/JCO.22.02572
Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression.
Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care.
LeVasseur, Nathalie MD 1,,; Gelmon, Karen A. MD 1,
doi : 10.1200/JCO.22.02863
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
Zeiser, Robert MD 1,
doi : 10.1200/JCO.22.02256
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data.
Alpert, Ash B. MD, MFA 1,2,; Brewer, Jamie Renee MD 3; Adams, Spencer BS 4; Rivers, Lexis MSN 5; Orta, Sunshine MAPS, PA-C 6; Blosnich, John R. PhD, MPH 7; Miedlich, Susanne MD 8,; Kamen, Charles PhD, MPH 9; Dizon, Don S. MD 10,; Pazdur, Richard MD 11; Beaver, Julia A. MD 11; Fashoyin-Aje, Lola MD, MPH 3,11
doi : 10.1200/JCO.22.01174
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst, Roy S. MD, PhD 1,; Wu, Yi-Long MD 2,; John, Thomas PhD 3,; Grohe, Christian MD 4,; Majem, Margarita MD, PhD 5,; Wang, Jie MD, PhD 6; Kato, Terufumi MD 7,; Goldman, Jonathan W. MD 8,; Laktionov, Konstantin PhD 9; Kim, Sang-We MD, PhD 10; Yu, Chong-Jen MD, PhD 11,12; Vu, Huu Vinh MD, PhD 13; Lu, Shun MD 14,; Lee, Kye Young MD, PhD 15,; Mukhametshina, Guzel MD 16; Akewanlop, Charuwan MD 17,; de Marinis, Filippo MD 18,; Bonanno, Laura MD 19,; Domine, Manuel MD, PhD 20,; Shepherd, Frances A. MD 21,; Urban, Damien MBBS 22,23,; Huang, Xiangning PhD 24,; Bolanos, Ana MD 25,; Stachowiak, Marta MPharm 26,; Tsuboi, Masahiro MD, PhD 27,
doi : 10.1200/JCO.22.02186
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
Speers, Corey W. MD, PhD 1,; Symmans, W. Fraser MD 2,; Barlow, William E. PhD 3,; Trevarton, Alex PhD 2; The, Stephanie MS 1; Du, Lili MD, PhD 2; Rae, James M. PhD 1; Shak, Steven MD 4,; Baehner, Rick MD 4,; Sharma, Priyanka MD 5,; Pusztai, Lajos MD, DPhil 6,; Hortobagyi, Gabriel N. MD 2,; Hayes, Daniel F. MD 1,; Albain, Kathy S. MD 7,; Godwin, Andrew PhD 5,; Thompson, Alastair MD 8,
doi : 10.1200/JCO.22.01499
Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS <= 25).
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
Lopes Cardozo, Josephine M.N. MD, PhD 1,2; Andrulis, Irene L. PhD 3,4; Bojesen, Stig E. MD, PhD 5,6,7; Dork, Thilo PhD 8; Eccles, Diana M. MD, PhD 9,; Fasching, Peter A. MD, PhD 10,; Hooning, Maartje J. PhD 11; Keeman, Renske MSc 12; Nevanlinna, Heli MD, PhD 13; Rutgers, Emiel J.T. MD, PhD 1,; Easton, Douglas F. PhD 14,15,; Hall, Per MD, PhD 16,17,;
doi : 10.1200/JCO.22.01978
A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Kitko, Carrie L. MD 1,,; Arora, Mukta MD, MS 2,; DeFilipp, Zachariah MD 3,; Zaid, Mohammad Abu MD 4,; Di Stasi, Antonio MD 5; Radojcic, Vedran MD 6,7,; Betts, Courtney B. PhD 8,; Coussens, Lisa M. PhD 8,; Meyers, Michael L. MD, PhD 7,; Qamoos, Hope MSN-NP 7,9; Ordentlich, Peter PhD 7,; Kumar, Vinit PhD 7,10; Quaranto, Christine BS 7,11,; Schmitt, Aaron BA 7,; Gu, Yu PhD 7,; Blazar, Bruce R. MD 12,; Wang, Trent P. DO 13; Salhotra, Amandeep MD 14,; Pusic, Iskra MD 15,; Jagasia, Madan MD 16,; Lee, Stephanie J. MD, MPH 17,
doi : 10.1200/JCO.22.00958
Chronic graft-versus-host disease (cGVHD) remains the major cause of late morbidity after allogeneic hematopoietic cell transplantation.
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos, David Bernard MD, PhD 1,; Abu Zaid, Mohammad MD 2,; Cooney, Julian P. MBBS 3,4; Albring, Jorn C. MD 5; Flowers, Mary MD 6,; Skarbnik, Alan P. MD 7,8,; Yakoub-Agha, Ibrahim MD, PhD 9,; Ko, Bor-Sheng MD, PhD 10,11,; Bruno, Benedetto MD, PhD 12,; Waller, Edmund K. MD, PhD 13,; Yared, Jean MD 14,; Sohn, Sang Kyun MD, PhD 15; Bulabois, Claude-Eric MD 16,; Teshima, Takanori MD, PhD 17,; Jacobsohn, David MD, MBA 18; Greinix, Hildegard MD 19,; Mokatrin, Ahmad PhD 20,; Lee, Yihua PhD 20; Wahlstrom, Justin T. MD 20,; Styles, Lori MD 20,; Socie, Gerard MD, PhD 21,
doi : 10.1200/JCO.22.00509
To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD).
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
Itzykson, Raphael MD, PhD 1,2,3,,; Santini, Valeria MD 4,5,; Thepot, Sylvain MD 3,6,; Ades, Lionel MD, PhD 1,3,7,; Chaffaut, Cendrine MSc 8; Giagounidis, Aristoteles MD 9,10,; Morabito, Margot BSc 11; Droin, Nathalie PhD 11; Lubbert, Michael MD 10,12,; Sapena, Rosa PhD 3; Nimubona, Stanislas MD 3,13; Goasguen, Jean MD 14; Wattel, Eric MD, PhD 3,15; Zini, Gina MD, PhD 16,17; Torregrosa Diaz, Jose Miguel MD 3,18; Germing, Ulrich MD 10,19,; Pelizzari, Anna Maria MD 5,20,; Park, Sophie MD, PhD 3,21,; Jaekel, Nadja MD 10,22,; Metzgeroth, Georgia MD 10,23,; Onida, Francesco MD 5,24,; Navarro, Robert MD 3,25; Patriarca, Andrea MD 5,26,; Stamatoullas, Aspasia MD 3,27,; Gotze, Katharina MD 10,28,; Puttrich, Martin MSc 10,29; Mossuto, Sandra MSc 5; Solary, Eric MD 3,11,30,; Gloaguen, Silke MSc 10,31; Chevret, Sylvie MD, PhD 8; Chermat, Fatiha DMD 3; Platzbecker, Uwe MD 10,31,; Fenaux, Pierre MD, PhD 1,3,7,
doi : 10.1200/JCO.22.00437
Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML).
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Li, Shao-Hua MD 1,2; Mei, Jie MD 1,2; Cheng, Yuan MD 3; Li, Qiang MD 4; Wang, Qiao-Xuan MD 2,5; Fang, Chong-Kai MD 6; Lei, Qiu-Cheng MD 7; Huang, Hua-Kun MD 3; Cao, Ming-Rong MD 4; Luo, Rui MD 6; Deng, Jing-Duo MD 3; Jiang, Yu-Chuan MD 4; Zhao, Rong-Ce MD 1,2; Lu, Liang-He MD 1,2; Zou, Jing-Wen MD 1,2; Deng, Min MD 1,2; Lin, Wen-Ping MD 1,2; Guan, Ren-Guo MD 1,2; Wen, Yu-Hua MD 1,2; Li, Ji-Bin MD 2,8; Zheng, Lie MD 2,9; Guo, Zhi-Xing MD 2,10; Ling, Yi-Hong MD 2,11; Chen, Huan-Wei MD 7; Zhong, Chong MD 6; Wei, Wei MD 1,2; Guo, Rong-Ping MD 1,2,
doi : 10.1200/JCO.22.01142
To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI).
Survival in Young Adults With Cancer Is Associated With Medicaid Expansion Through the Affordable Care Act.
Ji, Xu PhD 1,2,; Shi, Kewei Sylvia MPH 3; Mertens, Ann C. PhD 1,2,4; Zhao, Jingxuan MPH 3,; Yabroff, K. Robin PhD 3,; Castellino, Sharon M. MD, MSc 1,2; Han, Xuesong PhD 3,
doi : 10.1200/JCO.22.01742
Medicaid expansion through the Affordable Care Act (ACA) has been shown to improve insurance coverage and early diagnosis of cancer in young adults (YAs); whether these improvements translate to survival benefits remains unknown.
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
Erker, Craig MD, MS 1,,; Mynarek, Martin MD 2,3,; Bailey, Simon MBChB, PhD 4; Mazewski, Claire M. MD 5; Baroni, Lorena MD 6; Massimino, Maura MD 7,; Hukin, Juliette MB 8,; Aguilera, Dolly MD 5; Cappellano, Andrea M. MD 9; Ramaswamy, Vijay MD, PhD 10,; Lassaletta, Alvaro MD 11,; Perreault, Sebastien MD 12,; Kline, Cassie N. MD, MAS 13,; Rajagopal, Revathi MD 14;
doi : 10.1200/JCO.21.02968
Infant and young childhood medulloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive late effects. Unfortunately, many children relapse.
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.
Schmid, Maximilian P. MD 1,,; Lindegaard, Jacob C. MD 2; Mahantshetty, Umesh MD 3,; Tanderup, Kari PhD 2,; Jurgenliemk-Schulz, Ina PhD 4; Haie-Meder, Christine MD 5; Fokdal, Lars U. PhD 2; Sturdza, Alina MD 1; Hoskin, Peter MD 6,; Segedin, Barbara MD 7; Bruheim, Kjersti MD 8; Huang, Fleur MD 9; Rai, Bhavana MD 10; Cooper, Rachel MD 11; van der Steen-Banasik, Elzbieta MD 12; Van Limbergen, Erik PhD 13; Pieters, Bradley R. MD 14,; Petric, Primoz PhD 7; Ramazanova, Dariga BSc 15; Ristl, Robin PhD 15; Kannan, Sadhana PhD 3; Hawaldar, Rohini PhD 3; Ecker, Stefan BSc 1; Kirchheiner, Kathrin PhD 1; Tan, Li Tee MD 16; Nout, Remi MD 17,; Nesvacil, Nicole DSc 1,; de Leeuw, Astrid PhD 4; Potter, Richard MD 1,; Kirisits, Christian DSc 1,; for the EMBRACE Collaborative Group; Jurgenliemk-Schulz, Ina Maria; Huang, Fleur; Christiaens, Melissa; Janssen, Hilde; Sundset, Marit; Lutgens, Ludy C.H.W.; Villafranca, Elena; Hadjiev, Janaki; Bachand, Francois; Erickson, Beth; Jacobson, Geraldine; Anttila, Maarit; Dumas, Isabelle; Lowe, Gerry; Swamidas, Jamema; Hudej, Robert; Hellebust, Taran Paulsen; Menon, Geetha; Oinam, Arun S.; Bownes, Peter; De Brabandere, Marisol; Oosterveld, Bernard; Koedooder, Kees; Langeland Marthinsen, Anne Beate; Whitney, Diane; Ketelaars, Martijn; Reiniers, Brigitte; Mora, Itxa; Antal, Gergely; Batchelar, Deidre; Rownd, Jason; Kim, Yusung; Palmgren, Jan-Erik; Mazeron, Renaud; Chargari, Cyrus; Spampinato, Sofia
doi : 10.1200/JCO.22.01096
To report clinical and treatment characteristics, remission and failure patterns, and risk factors for local failure (LF) from the EMBRACE-I study.
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.
Vikas, Praveen MD 1,; Messersmith, Hans MPH 2; Compton, Carolyn MD, PhD 3,; Sholl, Lynette MD 4,; Broaddus, Russell R. MD 5; Davis, Anjee MPPA 6,; Estevez-Diz, Maria MD, PhD 7,; Garje, Rohan MD 8,; Konstantinopoulos, Panagiotis A. MD 9,; Leiser, Aliza MD 10; Mills, Anne M. MD 11; Norquist, Barbara MD 12; Overman, Michael J. MD 13,; Sohal, Davendra MD 14,; Turkington, Richard C. MD, PhD 15,; Johnson, Tyler MD 16,,
doi : 10.1200/JCO.22.02462
The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy.
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.
Cliff, Edward R. Scheffer MBBS, MPH; Reynolds, Gemma MChD, MIDI; Popat, Rakesh MBBS, PhD; Teh, Benjamin W. MBBS, PhD; Kesselheim, Aaron S. MD, JD, MPH; Mohyuddin, Ghulam Rehman MBBS
doi : 10.1200/JCO.22.02197
Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
Sun, Ryan PhD; Huang, Bo PhD; Wei, Lee-Jen PhD
doi : 10.1200/JCO.22.02596
